Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) fell 8.3% in the afternoon session after the company reported fourth-quarter revenue that missed Wall Street's ...

Abbott Laboratories has seen its implied fair value estimate edge to about US$144.75 from about US$144.43, a very small upward move that still matters for investors tracking the story closely. The ...

Recent Exact Sciences Corporation financials show accelerating revenue growth and stable margins, despite ongoing investments in screening and MRD. While EXAS maintains leadership in stool-based CRC ...

School is back in session for the pupils and teachers of Abbott Elementary after a much-needed winter break. After learning some not-so good news about the state of the school, the Abbott crew is ...

A new rapid test could improve treatment of urinary tract infections, by identifying the most effective antibiotic for each individual patient. The test applies different antibiotics to bacteria found ...

Rapid City, S.D. (KELO) – The Abbott House is expanding to western South Dakota with new homes and services in Rapid City. The Abbott House aims to fill gaps in services for young people who have ...

Students and guests attend an event hosted by the University of Texas chapter of Turning Point USA on campus in Austin, Monday, Nov. 3, 2025. Mikala Compton / Austin American-Statesman Gov. Greg ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott Laboratories ABT-0.83%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS-0.16%decrease; red down pointing triangle in a deal valued at about ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...